NPRL2 gene therapy

NPRL2 gene therapy is an investigational **gene therapy** that delivers the NPRL2 (Nitrogen Permease Regulator-Like 2, also known as TUSC4) tumor suppressor gene using a non-viral lipid nanoparticle system (DOTAP-NPRL2) such as the Oncoprex Delivery System, developed by Genprex.[1][9][10] NPRL2 is part of the GATOR1 complex and functions in cancer as a tumor suppressor. In preclinical cancer models—particularly anti-PD1 resistant, KRAS/STK11-mutant non-small cell lung cancer (NSCLC)—restoration of NPRL2 induces DNA damage, apoptosis, cell-cycle arrest, and sensitizes tumor cells to immune attack.[3][5] NPRL2 gene therapy acts by enhancing dendritic cell-mediated antigen presentation and activating cytotoxic T cells, diminishing immunosuppressive tumor microenvironment components (such as regulatory T cells, myeloid-derived suppressor cells), and inhibiting MAPK and AKT-mTOR signaling pathways.[3][5] The Oncoprex system is designed for intravenous administration and is specific for delivering tumor suppressor genes in a lipoplex formulation. NPRL2 gene therapy is currently in preclinical and investigational phases as a candidate for cancers resistant to immune checkpoint inhibitors, especially NSCLC with KRAS/STK11 mutations.[1][9]

Brand names

Oncoprex Delivery System

Other names

NPRL2 tumor suppressor gene therapyNPRL-2 tumor suppressor gene therapyNPRL 2 tumor suppressor gene therapyNPRL2/TUSC4 gene therapy